InnoSkel is developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which is spondyloepiphyseal dysplasia congenita, the second leading cause of dwarfism worldwide.

The French company's lead gene therapy asset for SEDc has demonstrated compelling efficacy in proof-of-concept studies.